Latest News about CYBN
Recent news which mentions CYBN
Cybin's Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder
June 28, 2022
Tickers
CYBN
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Psychedelic Stock Gainers And Losers From June 22, 2022
June 22, 2022
From Benzinga
10 Psychedelics CEOs To Pay Attention To In 2022
June 22, 2022
From Benzinga
From Benzinga
Psychedelic Stock Gainers And Losers From June 17, 2022
June 17, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From June 16, 2022
June 16, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From June 15, 2022
June 15, 2022
From Benzinga
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
June 15, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From June 14, 2022
June 14, 2022
From Benzinga
From Benzinga
From InvestorPlace
Cybin Moves Forward With Phase 1/2a Clinical Trial For Treatment Of Major Depressive Disorder
June 10, 2022
Tickers
CYBN
From Benzinga
Psychedelic Stock Gainers And Losers From June 10, 2022
June 10, 2022
From Benzinga
Elon Musk Says Psychedelics Should Be Seriously Considered For Therapeutic Uses, Leading Chorus Of Celeb Support
June 10, 2022
From Benzinga
From InvestorPlace
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Psychedelic Stock Gainers And Losers From June 3, 2022
June 03, 2022
From Benzinga
Cybin, GH Research Among Top Psychedelic Movers Of Today
June 02, 2022
From Benzinga
From Benzinga
From Benzinga
Major Depressive Disorder Could Soon Have Treatment Option Via Cybin's Psilocybin Analog
May 31, 2022
Tickers
CYBN
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.